Izorlisib is under clinical development by Stemline Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Izorlisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Izorlisib (MEN-1611) is under development for the treatment of advanced solid tumors including metastatic breast cancer, HER-2 positive breast cancer, invasive adenocarcinoma of the breast, colorectal cancer and non small cell lung cancer. It is administered orally. The drug candidate acts by targeting alpha-selective phosphatidylinositol 3 Kinase (PI3K) and HER2. It was also under development for the treatment of ovarian cancer, prostate cancer, and endometrial cancer.
Stemline Therapeutics overview
Stemline Therapeutics (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pipeline comprises of SL-401, SL-701, SL-801, SL-501 and SL-101. Stemline’s SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of hematologic cancers. The company’s SL-701 is an immunotherapy designed to activate the immune system to attack tumors. Its SL-801 is a novel oral small molecule reversible inhibitor of Exportin-1. Stemline is headquartered in New York, the US.
For a complete picture of Izorlisib’s drug-specific PTSR and LoA scores, buy the report here.